

Multi-side kinetic model to assess [1-13C]pyruvate in-vivo metabolism

PA Gómez^{1,2,3}, JI Sperl¹, O Khegai^{1,5}, MA Janich^{1,4,5}, F Wiesinger¹,
E Weidl⁴, SJ Glaser⁵, M Schwaiger⁴, RF Schulte¹, A Haase², MI Menzel¹

¹GE Global Research, Munich, Germany

²Medical Engineering, Technische Universität München, Munich, Germany

³Medical Engineering, Tecnológico de Monterrey, Monterrey, Mexico

⁴Nuclear Medicine, Technische Universität München, Munich, Germany

⁵Chemistry, Technische Universität München, Munich, Germany

1 Introduction

Hyperpolarized ¹³C imaging allows real-time in-vivo measurements of metabolic conversion. Experiments are performed by polarization of [1-¹³C]pyruvate with dynamic nuclear polarization and subsequent rapid dissolution, producing a hyperpolarized liquid suitable for intravenous injection[1]. In a previous study we examined the metabolic exchange between [1-¹³C]pyruvate and its downstream metabolites [1-¹³C]alanine, [1-¹³C]lactate, [1-¹³C]pyruvate hydrate and [¹³C]bicarbonate in male Wistar rats by acquiring slice-selective FID signals in slices dominated by heart, liver, and kidney tissue. Using pyruvate doses of 0.1 – 0.4 mmol/kg (body mass), we examined the effect of transient exposure to high pyruvate blood concentrations, causing potential saturation of cellular uptake and metabolic conversion, semi-quantitatively using signal-time integrals[2].

Further quantification of metabolite conversion can be achieved through kinetic modeling of time-domain signals. Present kinetic models represent a two-side interaction between pyruvate and one specific downstream metabolite[3,4]. Since pyruvate interacts dynamically and simultaneously with all of the downstream metabolites, the purpose of this work is the determination of parameter values through a multi-side, dynamic model involving all possible biochemical pathways.

2 Theory and Methods

Kinetic modeling parameters were determined by fitting the multi-side model to time-domain dynamic data (see Fig. 1). The model consists of a series of exponential equations similar to[4], but takes into account all of the metabolites into a one-step fitting process. The fitting was done in a least-squares sense and involved the gradient calculation of the parameters. Parameter values were compared with values of both two-side models and for different pyruvate doses and evaluated for statistically significant differences.




Fig. 1. Schematic representation of all possible metabolic pathways taken by [1- ^{13}C]pyruvate that can be visualized with NMR Spectroscopy (LDH = lactate dehydrogenase, ALT = alanine transaminase, PDC = pyruvate dehydrogenase complex, CA = carbonic anhydrase) and metabolic time fit of data acquired for a 0.4 mmol/kg dose in kidney predominant tissue. The yellow square represents the two-side exchange kinetic model, in this case between [1- ^{13}C]pyruvate and [1- ^{13}C]alanine. The proposed model takes into account not only this single pyruvate-to-metabolite exchange, but includes all of the metabolites represented in the diagram.

3 Results

The model presented was shown to be robust and have an optimal convergence point. In comparison to the two-side exchange models, the multi-side model yielded smaller pyruvate-to-metabolite exchange rates and improved determination of T1 values for pyruvate. Dose effects observed in [2] were confirmed and quantified through pyruvate-to-metabolite exchange rate values (results will be presented at the conference).

4 Conclusions

The proposed kinetic modeling method that takes into account all of the downstream metabolites in one system can be used for the quantification of pyruvate metabolic exchange rates. Parameter interdependency allowed a more accurate quantification than other modeling methods and can therefore be useful for the monitoring of metabolic activity in different tissues.

References

1. Ardenkjaer-Larsen, J.H., Fridlund, B., Gram, A., Hansson, G., Hansson, L., Lerche, M.H., Servin, R., Thaning, M., Golman, K.: Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. *Proceedings of the National Academy of Sciences* 100(18), 10158–63 (2003)
2. Janich, M.A., Menzel, M.I., Wiesinger, F., Weidl, E., Khagai, O., Ardenkjaer-Larsen, J.H., Glaser, S.J., Haase, A., Schulte, R.F., Schwaiger, M.: Effects of pyruvate dose on in vivo metabolism and quantification of hyperpolarized ^{13}C spectra. *NMR in Biomedicine* 25(1), 142–151 (2012)
3. Wiesinger, F., Miederer, I., Menzel, M.I., Weidl, E., Janich, M., Ardenkjaer-Larsen, J.H., Schwaiger, M., Schulte, R.F.: Metabolic rate constant mapping of hyperpolarized ^{13}C pyruvate. *ISMRM* (2010)
4. Zierhut, M.L., Yen, Y.F., Chen, A.P., Bok, R., Albers, M.J., Zhang, V., Tropp, J., Park, I., Vigneron, D.B., Kurhanewicz, J., Hurd, R.E., Nelson, S.J.: Kinetic modeling of hyperpolarized ^{13}C -pyruvate metabolism in normal rats and TRAMP mice. *Journal of Magnetic Resonance* 202(1), 85–92 (2010)